Published in Blood Weekly, September 6th, 2001
"Epstein-Barr virus lymphoproliferative disease (EBV-LPD) following allogeneic stem cell transplantation (allo-SCT) has a poor prognosis," according to J.W.J. van Esser and colleagues at the University of Rotterdam Hospital.
However, the use of quantitative, real-time polymerase chain reaction (PCR) analysis to keep track of EPV loads allows doctors to rapidly determine the effectiveness of treatment...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.